Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537155 | 0.88 | KHK (0.42) | KHKFGFR1FGFR2ALDH1A1HPGD | |
| SCHEMBL3542577 | 0.87 | KHK (0.41) | KHKFGFR1FGFR2LCKMAPT | |
| SCHEMBL3535903 | 0.87 | LCK (0.47) | KHKFGFR1FGFR2LCKKDM4E | |
| SCHEMBL3537657 | 0.85 | PRKDC (0.46) | PRKDCKHKFGFR1FGFR2MAPT | |
| SCHEMBL3540020 | 0.83 | LMNA (0.44) | KHKFGFR1FGFR2LCKMAPT | |
| SCHEMBL3544838 | 0.82 | ABL1 (0.53) | KHKFGFR1FGFR2MAPTDRD2 | |
| SCHEMBL3536581 | 0.79 | ABL1 (0.52) | FGFR1FGFR2KDM4EALDH1A1FGFR3 | |
| SCHEMBL3533624 | 0.79 | ABL1 (0.55) | PRKDCKHKFGFR1FGFR2KDM4E | |
| SCHEMBL3538866 | 0.79 | FGFR1 (0.51) | KHKFGFR1FGFR2MAPTKDM4E | |
| SCHEMBL3541251 | 0.78 | RAB9A (0.45) | FGFR1MAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745454-B2 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | PRKDC 4692/4885KHK 3627/4885FGFR1 2690/4885 |
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | PRKDC 50/4885KHK 2560/4885FGFR1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.